Key result
Omega-3 fatty acids reduce residual cardiovascular risk in CAD, potentially dependent on baseline EPA/AA ratios.
Answers are grounded in this paper and cite their sources.
Residual risk, which cannot be prevented by statins alone, must be controlled for inhibiting the onset of coronary events. Omega-3 polyunsaturated fatty acids (PUFAs) play an important role in controlling residual risk. The Japan eicosapentaenoic acid (EPA) Lipid Intervention Study demonstrated the inhibitory effect of high-purity EPA preparations on the residual risk of cardiovascular events. Omega-3 PUFAs inhibit coronary artery disease (CAD) through various actions, including triglyceride-lowering action. Besides lipid metabolism, platelet aggregation inhibition, anti-inflammatory effects, improved vascular endothelium function, and anti-hypertensive action contribute to arteriosclerosis inhibition. Conversely, several recent studies did not demonstrate the efficacy of omega-3 PUFAs for CAD prevention. PUFAs levels may need to exceed a threshold for anti-arteriosclerotic action. The efficacy of EPA might depend on the baseline value of the EPA/arachidonic acid (AA) ratio prior to EPA administration. This baseline EPA/AA ratio value varies according to country and region as well as changes of dietary habits. More global research in this field is needed to identify an optimal omega-3 PUFAs administration strategy.
No takes yet. Share an insight, caveat, or question.
Nishizaki et al. (2017) conducted a review in Coronary artery disease. Omega-3 polyunsaturated fatty acids (EPA) was evaluated on Residual risk of cardiovascular events and coronary artery disease prevention. Omega-3 polyunsaturated fatty acids reduce residual cardiovascular risk in coronary artery disease, though efficacy may depend on baseline EPA/arachidonic acid ratios.
Synapse has enriched 10 related papers. Consider them for comparative context: